

SUPPLEMENTAL


Supplemental Table 1: Baseline characteristics of the 107 individuals included. Data are expressed as median [interquartile range] parentheses after variable name, depict units, and, if applicable, reference values. BMI: body mass index, AF: alkaline phosphatase, g-GT: gamma glutamyl transferase, ALAT: alanine aminotransferase, ASAT: aspartate aminotransferase, FPG: fasting plasma glucose, HbA1c: Hemoglobin A1c, HDL: high-density lipoprotein, LDL: low-density lipoprotein.

Variables	All n=107
Sex (male/female)	24/83
Age (years)	45 [40 – 53]
BMI (kg/m ²)	39.5 [37 – 41]
Diabetes (n)	22
AF (30-135 U/L)	80 [69 – 97]
g-GT (10 – 40 U/l)	25 [18 - 39]
ALAT (0 - 50 U/l)	27 [21 - 42]
ASAT (0 – 35 U/l)	24 [20 - 28]
Ferritin (24 – 336 ug/l)	104 [48 - 182]
FPG (<5.6 mmol/l)	5.5 [5.1 – 6.3]
HbA1c (<5.6 %)	5.7 [5.4 – 6.0]
HbA1c (mmol/mol)	39 [36 – 42]
Fasting insulin (18-48 pmol/l)	83 [55 – 122]
Total cholesterol (1.5 – 6.5 mmol/l)	4.7 [4.1 – 5.6]
Triglycerides (<1.7 mmol/l)	1.2 [0.9 – 1.6]
HDL cholesterol (≥1.0 mmol/l)	1.2 [1.0 – 1.4]
LDL cholesterol (< 3.0 mmol/l)	3.0 [2.4 – 3.7]


Supplementary Table 2: Baseline characteristics of 180 subjects from the KOBS study. Data are expressed as median [interquartile range] and parentheses after variable name, depict units and, if applicable, reference values. BMI: body mass index, AF: alkaline phosphatase, g-GT: gamma glutamyl transferase, ALAT: alanine aminotransferase, ASAT: aspartate aminotransferase, FPG: fasting plasma glucose, HbA1c: Hemoglobin A1c, HDL: high-density lipoprotein, LDL: low-density lipoprotein.


All		
n		180
sex (%)	male	53 (29.4)
	female	127 (70.6)
T2D (%)	no	121 (67.2)
	yes	59 (32.8)
Age years (median [IQR])		47.95 [42.34, 54.98]
BMI kg/m ² (median [IQR])		42.35 [39.27, 45.76]
Alat U/l (median [IQR])		33.00 [25.00, 49.00]
Cholesterol mmol/l (mean(SD))		4.14 (0.87)
HDL mmol/l (median [IQR])		1.07 [0.91, 1.26]
LDL mmol/l (mean(SD))		2.33 (0.80)
Triglycerides mmol/l (median [IQR])		1.40 [1.06, 1.88]
Glucose mmol/l (median [IQR])		6.00 [5.40, 6.60]
Insulin pmol/l (median [IQR])		109.72 [70.83, 152.08]
NAFLD status (%)	No steatosis	87 (48.3)
	NAFL	41 (22.8)
	NASH	52 (28.9)

Supplemental Figure 1. Positive controls of p21 and p53 staining. A. 100 times magnification of p21 positive control. B. 200 times magnification of p21 positive control. C. 100 times magnification of p53 positive control. D. 200 times magnification of p53 positive control.



Supplemental Figure 2: Representative images of immunohistochemistry staining of liver tissue with BCL-2 with respectively 100-, 200- and 400-times magnification.





Supplemental Figure 3. A: Boxplot of the percentage BCL-2 and p53 on the y-axis and ADA categories on the x-axis. Significance level calculated with Kruskal-Wallis rank sum test is displayed. **B-E:** Percentages of BCL-2 and p53 are on the y-axis and fasting glucose, glucose AUC, fasting peripheral insulin, and insulin AUC are on the x axis. The blue line is linear regression prediction line, grey is the 95% confidence interval of the regression, rho is the Spearman correlation coefficient, and p-value is the significance level.